APRE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
APRE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aprea Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $4.54.
During the past 12 months, Aprea Therapeutics's average Book Value per Share Growth Rate was -53.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was -60.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of Aprea Therapeutics was -56.60% per year. The lowest was -60.40% per year. And the median was -58.50% per year.
For the Biotechnology subindustry, Aprea Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Aprea Therapeutics's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Aprea Therapeutics (NAS:APRE) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Thank you for viewing the detailed overview of Aprea Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Jean-pierre Bizzari | director | 235 LAUREL LN, HAVERFOLD PA 19041 |
Bernd R. Seizinger | director | 535 BOYLSTON STREET, BOSTON MA 02116 |
Gabriela Gruia | director | C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
John P. Hamill | officer: SrVP/CFO/Prin. Fin &Acctg. Off | 4092 NEW HOPE ROAD, FURLONG PA 18925 |
Michael Grissinger | director | C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116 |
Marc Duey | director | 27 STRATHMORE ROAD, NATICK MA 01760 |
Oren Gilad | officer: President, CEO | 535 BOYLSTON STREET, BOSTON MA 02116 |
Rifat Pamukcu | director | 535 BOYLSTON STREET, BOSTON MA 02116 |
Christian S Schade | director, officer: President & CEO | MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540 |
Eyal C. Attar | officer: SVP, Chief Medical Officer | 535 BOYLSTON STREET, BOSTON MA 02116 |
Gregory Alan Korbel | officer: Chief Business Officer | 535 BOYLSTON STREET, BOSTON MA 02116 |
Lars B. Abrahmsen | officer: SVP, Chief Scientific Officer | 535 BOYLSTON STREET, BOSTON MA 02116 |
Jeremy Green | 10 percent owner | 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001 |
Redmile Group, Llc | 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
5am Ventures Iv, L.p. | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
From GuruFocus
By Marketwired • 10-16-2023
By Value_Insider Value_Insider • 11-09-2022
By sperokesalga sperokesalga • 03-01-2023
By sperokesalga sperokesalga • 02-23-2023
By GuruFocusNews GuruFocusNews • 06-25-2022
By GuruFocusNews GuruFocusNews • 06-05-2022
By Marketwired • 09-19-2023
By Stock market mentor Stock market mentor • 01-19-2023
By sperokesalga sperokesalga • 05-30-2023
By sperokesalga sperokesalga • 06-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.